Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diclofenac - Amzell

Next Previous
X
Search
Drug Profile

Diclofenac - Amzell

Alternative Names: AMZ-001; Diclofenac gel 3.06% - Amzell; Diclofenac sodium gel - Amzell

Latest Information Update: 18 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amzell
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Pain

Most Recent Events

  • 29 Nov 2024 Phase-I clinical trials in Pain (In volunteers) in Germany (Topical) (NCT06729073)
  • 19 Nov 2024 Amzell plans a phase III trial for Pain in USA, Czech Republic, Denmark, China (Topical, Gel) in January 2025 (NCT06693648) (EudraCT2024-517404-11)
  • 11 Jul 2023 Amzell initiates a phase I pharmacokinetic and safety trial in healthy volunteers (Topical) in USA (NCT05968482)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top